CSIMarket
 


Ligand Pharmaceuticals Incorporated  (LGND)
Other Ticker:  
 
 

LGND's EPS Net Growth by Quarter and Year

Ligand Pharmaceuticals Incorporated's EPS Net results by quarter and year




LGND EPS Net (in $) FY 2023 FY 2022 FY 2021 FY 2020
IV Quarter December - -1.04 -0.31 0.36
III Quarter September -0.59 0.02 0.80 -0.42
II Quarter June 0.13 -0.05 1.79 1.32
I Quarter March 2.33 -0.91 1.05 -1.46
FY   1.87 -1.98 3.33 -0.20



LGND EPS Net third quarter 2023 Y/Y Growth Comment
Ligand Pharmaceuticals Incorporated in the third quarter 2023 recorded EPS net loss of $ -0.59 .

According to the results reported in the third quarter 2023, Ligand Pharmaceuticals Incorporated achieved the best EPS Net growth in Major Pharmaceutical Preparations industry. While Ligand Pharmaceuticals Incorporated' s EPS Net no change of % ranks overall at the positon no. in the third quarter 2023.




LGND EPS Net ( Y/Y Growth %) 2023
2022 2021 2020
IV Quarter December - - - -
III Quarter September - -97.5 % - -
II Quarter June - - 35.61 % -
I Quarter March - - - -
FY   - - - -

Financial Statements
Ligand Pharmaceuticals Incorporated's third quarter 2023 EPS Net $ -0.59 LGND's Income Statement
Ligand Pharmaceuticals Incorporated's third quarter 2022 EPS Net $ 0.02 Quarterly LGND's Income Statement
New: More LGND's historic EPS Net Growth >>


LGND EPS Net (Quarter on Quarter Growth %)

2023
2022 2021 2020
IV Quarter December - - - -
III Quarter September - - -55.31 % -
II Quarter June -94.42 % - 70.48 % -
I Quarter March - - 191.67 % -
FY (Year on Year)   - - - -




EPS Net third quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

EPS Net Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 
EPS Net third quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
EPS Net Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 

EPS Net by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Ligand Pharmaceuticals Incorporated's Q/Q EPS Net Growth


EPS Net Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


LGND's III. Quarter Q/Q EPS Net Comment
III. Quarter 2023 results of -0.59 by Ligand Pharmaceuticals Incorporated look even worse considering the EPS net loss 0.13 in the previous quarter.

Within Major Pharmaceutical Preparations industry Ligand Pharmaceuticals Incorporated achieved highest sequential EPS Net growth. While Ligand Pharmaceuticals Incorporated's EPS Net growth quarter on quarter, overall rank is .


EPS Net Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
EPS Net Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
EPS Net Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


LGND's III. Quarter Q/Q EPS Net Comment
Current accomplishment of -0.59 by Ligand Pharmaceuticals Incorporated appear even more unfavourable compare to the 0.13 in the previous quarter.

Within Major Pharmaceutical Preparations industry Ligand Pharmaceuticals Incorporated achieved highest sequential EPS Net growth. While Ligand Pharmaceuticals Incorporated's EPS Net growth quarter on quarter, overall rank is .


Ligand Pharmaceuticals Incorporated's 12 Months EPS Net Growth Year on Year


EPS Net TTM Growth

12 Months Ending
(Sep 30 2023)
12 Months Ending
(Jun 30 2023)
12 Months Ending
(Mar 31 2023)
12 Months Ending
(Dec 31 2022)
12 Months Ending
(Sep 30 2022)
Cumulative EPS Net 12 Months Ending $ 0.83 $ 1.44 $ 1.26 $ -1.98 $ -1.25
Y / Y EPS Net Growth (TTM) - - -7.61 % - -
Year on Year EPS Net Growth Overall Ranking # 872 # 1142 # 1497 # 1621 # 1531
Seqeuential EPS Net Change (TTM) -42.22 % 14.23 % - - -
Seq. EPS Net Growth (TTM) Overall Ranking # 527 # 710 # 1680 # 1357 # 0




Cumulative EPS Net growth Comment
In the Sep 30 2023 period, Ligand Pharmaceuticals Incorporated had cumulative twelve months EPS Net of $ 1 compare to EPS net loss of $ -1 a year ago.

In the Healthcare sector 55 other companies have achieved higher trailing twelve month EPS Net growth. While Total ranking has impoved so far to 872, from total ranking in previous quarter at 1142.

EPS Net TTM Q/Q Growth Statistics
High Average Low
3663.95 %
420.07 %
-159.33 %
 

EPS Net TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 10
Healthcare Sector # 56
Overall # 872

EPS Net TTM Y/Y Growth Statistics
High Average Low
3663.95 %
420.07 %
-159.33 %
 


EPS Net TTM Q/Q Growth Company Ranking
Within: No.
Industry # 10
Sector # 38
S&P 500 # 527
Cumulative EPS Net growth Comment
In the Sep 30 2023 period, Ligand Pharmaceuticals Incorporated had cumulative twelve months EPS Net of $ 1 compare to EPS net loss of $ -1 a year ago.

In the Healthcare sector 55 other companies have achieved higher trailing twelve month EPS Net growth. While Total ranking has impoved so far to 872, from total ranking in previous quarter at 1142.

EPS Net TTM Q/Q Growth Statistics
High Average Low
3663.95 %
420.07 %
-159.33 %
 


EPS Net TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 10
Healthcare Sector # 56
Overall # 872

EPS Net TTM Y/Y Growth Statistics
High Average Low
3663.95 %
420.07 %
-159.33 %
 


EPS Net TTM Q/Q Growth Company Ranking
Within: No.
Industry # 10
Sector # 38
S&P 500 # 527




Other EPS Net Growth
Major Pharmaceutical Preparations Industry EPS Net Growth Trends and Statistics
Healthcare Sector EPS Net Growth Statistics
EPS Net Growth Trends for overall market
LGND's EPS Net Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking EPS Net Growth
Lowest Ranking EPS Net Growth
EPS Net Growth for LGND's Competitors
EPS Net Growth for Ligand Pharmaceuticals Incorporated's Suppliers
EPS Net Growth for LGND's Customers

You may also want to know
LGND's Annual Growth Rates LGND's Profitability Ratios LGND's Asset Turnover Ratio LGND's Dividend Growth
LGND's Roe LGND's Valuation Ratios LGND's Financial Strength Ratios LGND's Dividend Payout Ratio
LGND's Roa LGND's Inventory Turnover Ratio LGND's Growth Rates LGND's Dividend Comparisons



Companies with similar EPS Net no change for the quarter ending Sep 30 2023 within Healthcare SectorY/Y Change %EPS Net for the quarter ending Sep 30 2023
National Research Corporation-3.03%$ -3.030 
Henry Schein Inc-3.67%$ -3.670 
Universal Health Services Inc -4.00%$ -4.000 
Mettler toledo International Inc -5.64%$ -5.635 
The Pennant Group Inc -6.25%$ -6.250 
Corcept Therapeutics Inc-6.67%$ -6.667 
Viatris Inc -6.90%$ -6.897 
Quest Diagnostics Inc-9.68%$ -9.677 
Charles River Laboratories International inc -10.11%$ -10.106 
Stryker Corp-15.89%$ -15.888 
Zimmer Biomet Holdings Inc -16.30%$ -16.304 
Tenet Healthcare Corp-18.97%$ -18.966 
Amgen Inc -19.10%$ -19.095 
Hologic Inc-22.69%$ -22.688 
Zynex inc -23.08%$ -23.077 
Dariohealth Corp -23.44%$ -23.438 
Regeneron Pharmaceuticals Inc -23.76%$ -23.756 
Entera Bio Ltd -27.27%$ -27.273 
U S Physical Therapy Inc-29.17%$ -29.167 
Pediatrix Medical Group Inc -29.73%$ -29.730 
Avantor Inc -36.00%$ -36.000 
Ufp Technologies Inc -40.63%$ -40.625 
Biomx Inc -43.48%$ -43.478 
Laboratory Corporation Of America Holdings-45.90%$ -45.897 
Royalty Pharma Plc-50.00%$ -50.000 
Staar Surgical Company-52.38%$ -52.381 
Abbvie inc -54.75%$ -54.751 
Repligen Corp-54.93%$ -54.930 
Envista Holdings Corporation-55.56%$ -55.556 
Oramed Pharmaceuticals Inc -55.56%$ -55.556 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com